DDInter298 DDInter140
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and slow onset of action. Many if not most gold compounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far more effective.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aurothioglucose
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aurothioglucose
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is upregulated by {v} (Compound) Teniposide
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aurothioglucose
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aurothioglucose
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aurothioglucose
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aurothioglucose
Carboplatin {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Thalidomide
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aurothioglucose
Carboplatin {u} (Compound) causes {v} (Side Effect) Phlebitis
Phlebitis {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Aurothioglucose
Carboplatin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Aurothioglucose
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carboplatin (Compound) binds SLC31A2 (Gene) and SLC31A2 (Gene) is upregulated by Teniposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carboplatin (Compound) binds SLC31A1 (Gene) and SLC31A1 (Gene) is bound by Bortezomib (Compound) and SLC31A1 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Oxaliplatin (Compound) and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carboplatin (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Thalidomide (Compound) and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Carboplatin (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Aurothioglucose
Carboplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Aurothioglucose